Mitsubishi Tanabe Pharma Corporation

Joji Tsurumoto

Takeshi Uemura

Hiroshi Miyazaki

Kenji Morokuma

Takao Komasaka

Yuuji Morita

The present invention provides: a methyl 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-disulfonic acid which is represented by formula (1) and is excellent in crystallinity; and a method for producing the same; and a production intermediate thereof; and a production method using this compound.

Optically active pyrrolidine compound and method for producing same

The present invention provides novel crystal forms of arylalkylamine compounds. Specifically, the novel crystal forms of 4-(3S-(1R-(1-naphthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid have excellent stability and therefore are useful as pharmaceutical ingredients. The present invention also provides industrially advantageous processes for producing the arylalkylamine compounds.

Crystalline arylalkylamine compound and process for producing the same

The present invention provides crystal forms A and B of 4-(3S-(1R-(1-naphthyl)ethylamino)pyrrolidin-1-yl)phenylacetic acid having excellent stability and use as pharmaceutical ingredients. The present invention also provides industrially advantageous processes for producing these crystalline compounds.

Growing community of inventors

Osaka, Japan

Joji Tsurumoto